Analyst Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Aligos Therapeutics and keeping the price target at $50.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Patrick Trucchio has given his Buy rating due to a combination of factors that highlight Aligos Therapeutics’ promising developments in their viral and metabolic liver disease programs. The company presented compelling data at the HEP-DART 2025 conference, showcasing the potential of their therapies in these areas. Notably, the Phase 1 trial of pevifoscorvir sodium demonstrated durable viral suppression and antigen reduction without resistance, reinforcing its potential as a first-in-class treatment for chronic hepatitis B virus suppression.
Additionally, Aligos’ ALG-055009 showed significant synergistic weight-loss effects when combined with incretin receptor agonists, suggesting a best-in-class profile for obesity and metabolic dysfunction-associated steatohepatitis therapies. These advancements, along with a favorable safety profile and ongoing global partnership explorations, underpin the company’s strategic pipeline. The valuation model, which considers a risk-adjusted methodology, supports a $50 price target, despite acknowledging potential risks such as clinical development and regulatory challenges.